CD274 and non-small cell lung carcinoma: In this study, we analyzed a cohort of 88 patients with advanced NSCLC and PD-L1 TPS ≥ 50% treated in first-line with pembrolizumab and we investigated the influence of the Eastern Cooperative Oncology Group Stage Performance Status (ECOG PS) as a possible prognostic factor of survival.